Health Catalyst, Inc. (NASDAQ:HCAT) Given Average Rating of “Hold” by Brokerages

Shares of Health Catalyst, Inc. (NASDAQ:HCAT) have received an average recommendation of “Hold” from the fourteen ratings firms that are presently covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, eight have assigned a hold recommendation and five have given a buy recommendation to the company. The average 12 month target price among brokers that have updated their coverage on the stock in the last year is $4.3636.

Several research analysts have issued reports on the stock. Stifel Nicolaus lowered their price target on shares of Health Catalyst from $4.50 to $3.75 and set a “hold” rating for the company in a report on Tuesday, November 11th. Evercore ISI lowered their target price on shares of Health Catalyst from $4.00 to $3.00 and set an “in-line” rating for the company in a research note on Wednesday, October 8th. Citigroup cut their price target on shares of Health Catalyst from $3.50 to $3.25 and set a “neutral” rating on the stock in a research report on Tuesday, November 11th. Weiss Ratings reissued a “sell (e+)” rating on shares of Health Catalyst in a research report on Monday, December 29th. Finally, KeyCorp dropped their price objective on Health Catalyst from $5.00 to $4.00 and set an “overweight” rating on the stock in a research note on Wednesday, October 8th.

Insider Activity at Health Catalyst

In related news, General Counsel Benjamin Landry sold 27,425 shares of the business’s stock in a transaction on Friday, December 5th. The shares were sold at an average price of $2.64, for a total transaction of $72,402.00. Following the transaction, the general counsel owned 100,000 shares in the company, valued at $264,000. The trade was a 21.52% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Julie Larson-Green sold 47,997 shares of the firm’s stock in a transaction on Thursday, December 4th. The stock was sold at an average price of $2.67, for a total transaction of $128,151.99. Following the completion of the sale, the director owned 73,573 shares of the company’s stock, valued at $196,439.91. The trade was a 39.48% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 2.60% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Health Catalyst

Several institutional investors have recently made changes to their positions in HCAT. Pilgrim Partners Asia Pte Ltd acquired a new stake in shares of Health Catalyst in the 3rd quarter valued at about $39,000. Cresset Asset Management LLC acquired a new position in Health Catalyst during the 2nd quarter worth approximately $39,000. Divergent Planning LLC bought a new position in Health Catalyst in the second quarter worth approximately $45,000. FNY Investment Advisers LLC bought a new position in Health Catalyst in the third quarter worth approximately $45,000. Finally, Focus Partners Wealth acquired a new stake in Health Catalyst in the first quarter valued at approximately $46,000. Institutional investors and hedge funds own 85.00% of the company’s stock.

Health Catalyst Stock Down 4.6%

Shares of HCAT opened at $2.28 on Tuesday. The stock’s 50-day moving average price is $2.64 and its two-hundred day moving average price is $3.11. Health Catalyst has a 12 month low of $2.02 and a 12 month high of $7.65. The company has a market capitalization of $161.26 million, a PE ratio of -1.43 and a beta of 1.69. The company has a current ratio of 1.88, a quick ratio of 1.88 and a debt-to-equity ratio of 0.46.

Health Catalyst (NASDAQ:HCAT) last issued its quarterly earnings data on Monday, November 10th. The company reported $0.06 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.05 by $0.01. The company had revenue of $76.32 million during the quarter, compared to the consensus estimate of $75.05 million. Health Catalyst had a negative return on equity of 6.67% and a negative net margin of 34.05%. On average, analysts anticipate that Health Catalyst will post -0.33 EPS for the current year.

Health Catalyst Company Profile

Health Catalyst (NASDAQ: HCAT) is a healthcare data and analytics technology company founded in 2008 and headquartered in Salt Lake City, Utah. The company went public in 2019 and has since focused on delivering a unified data platform that helps healthcare organizations aggregate and analyze clinical, financial and operational information.

The core of Health Catalyst’s offering is the Data Operating System (DOS), a modular data management platform that integrates disparate data sources—from electronic health records to claims and patient-generated data—into a single analytics environment.